| MeSH term | MeSH ID | Detail |
|---|---|---|
| Thrombocytosis | D013922 | 4 associated lipids |
| Optic Nerve Injuries | D020221 | 4 associated lipids |
| Asphyxia Neonatorum | D001238 | 4 associated lipids |
| Hyperuricemia | D033461 | 4 associated lipids |
| Bronchopulmonary Dysplasia | D001997 | 4 associated lipids |
| Viremia | D014766 | 4 associated lipids |
| AIDS Dementia Complex | D015526 | 4 associated lipids |
| Neoplasms, Germ Cell and Embryonal | D009373 | 4 associated lipids |
| Burns, Inhalation | D002059 | 4 associated lipids |
| Shock, Traumatic | D012774 | 4 associated lipids |
Platelet activating factor
Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
Cross Reference
Introduction
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Platelet activating factor?
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- J. Lipid Res. (5)
- Proc. Natl. Acad. Sci. U.S.A. (2)
- Am. J. Physiol. Gastrointest. Liver Physiol. (2)
- Others (26)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
PubChem Associated disorders and diseases
What pathways are associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Platelet activating factor?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Platelet activating factor?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Platelet activating factor?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Platelet activating factor?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Platelet activating factor?
Knock-out
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Platelet activating factor
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Mishra RK et al. | Differential dependence of eosinophil chemotactic responses on phosphoinositide 3-kinase (PI3K). | 2005 | Allergy | pmid:16076309 |
| Schauer U et al. | Enhanced production of platelet activating factor by peripheral granulocytes from children with asthma. | 1992 | Allergy | pmid:1514664 |
| Egesten A and Malm J | Eosinophil leukocyte degranulation in response to serum-opsonized beads: C5a and platelet-activating factor enhance ECP release, with roles for protein kinases A and C. | 1998 | Allergy | pmid:9860239 |
| Woo HY et al. | Mechanism for acute oral desensitization to antibiotics. | 2006 | Allergy | pmid:16867049 |
| Howarth PH | Mediators of nasal blockage in allergic rhinitis. | 1997 | Allergy | pmid:9353555 |
| Zuberbier T et al. | Histamine releasability of basophils and skin mast cells in chronic urticaria. | 1996 | Allergy | pmid:8721524 |
| Zeck-Kapp G et al. | Mechanisms of human eosinophil activation by complement protein C5a and platelet-activating factor: similar functional responses are accompanied by different morphologic alterations. | 1995 | Allergy | pmid:7741187 |
| Krause K et al. | Platelet-activating factor (PAF) induces wheal and flare skin reactions independent of mast cell degranulation. | 2013 | Allergy | pmid:23320562 |
| Dunoyer-Geindre S et al. | PAF acether release on antigenic challenge. A method for the investigation of drug allergic reactions. | 1992 | Allergy | pmid:1590567 |
| Mullol J et al. | Rupatadine in allergic rhinitis and chronic urticaria. | 2008 | Allergy | pmid:18339040 |
| Takafuji S et al. | Effects of interleukin (IL)-3 and IL-5 on human eosinophil degranulation induced by complement components C3a and C5a. | 1996 | Allergy | pmid:8874660 |
| Di Leo E et al. | Treatment of acquired cold urticaria with rupatadine. | 2009 | Allergy | pmid:19392988 |
| Soyombo O et al. | Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. | 1994 | Allergy | pmid:8037356 |
| Takafuji S et al. | Release of granule proteins from human eosinophils stimulated with mast-cell mediators. | 1998 | Allergy | pmid:9821474 |
| Maniscalco M et al. | The effect of platelet-activating factor (PAF) on nasal airway resistance in healthy subjects is not mediated by nitric oxide. | 2000 | Allergy | pmid:10955702 |
| Mukai K et al. | New insights into the roles for basophils in acute and chronic allergy. | 2009 | Allergol Int | pmid:19153532 |
| Negro Alvarez JM et al. | Platelet-activating factor antagonists. | 1997 Sep-Oct | Allergol Immunopathol (Madr) | pmid:9395010 |
| MonteseirÃn J et al. | Formation of lipids, peptides and cytokines. | 1996 Sep-Oct | Allergol Immunopathol (Madr) | pmid:8985477 |
| Miadonna A et al. | Induction and control of allergic inflammation in human respiratory airways. | 1993 May-Jun | Allergol Immunopathol (Madr) | pmid:7689291 |
| Rihoux JP | [Allergic reaction and vascular permeability]. | 1990 | Allerg Immunol (Paris) | pmid:2288644 |
| Beauvais F and Benveniste J | [IgE and anaphylaxis mediators]. | 1987 | Allerg Immunol (Paris) | pmid:2968802 |
| Mencia-Huerta JM et al. | [Effect of long-term administration of platelet activating factor on pulmonary response and morphology in the guinea pig]. | 1988 | Allerg Immunol (Paris) | pmid:3245884 |
| Ligumsky M et al. | The role of platelet activating factor [correction of actor] in acute gastric injury and its protection by sucralfate. | 1990 | Aliment. Pharmacol. Ther. | pmid:2129638 |
| Greenberg SS et al. | Ethanol suppresses endotoxin but not platelet activating factor-induced hypotension and nitric oxide. | 1996 | Alcohol. Clin. Exp. Res. | pmid:8904980 |
| Saleh AA et al. | Effect of alcohol on platelet-activating factor acetylhydrolase activity in pregnant and nonpregnant mice. | 1994 | Alcohol. Clin. Exp. Res. | pmid:7978079 |
| Baker RC et al. | Effects of ethanol on human platelets stimulated with platelet-activating factor, a biologically active ether phospholipid. | 1989 | Alcohol. Clin. Exp. Res. | pmid:2557776 |
| Lands WE | Cellular signals in alcohol-induced liver injury: a review. | 1995 | Alcohol. Clin. Exp. Res. | pmid:7485841 |
| Kelesidis T et al. | The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection. | AIDS Rev | pmid:26616844 | |
| Chini M et al. | Effects of HAART on platelet-activating factor metabolism in naive HIV-infected patients I: study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen. | 2012 | AIDS Res. Hum. Retroviruses | pmid:22050695 |
| Lima RG et al. | Interaction of macrophages with apoptotic cells enhances HIV Type 1 replication through PGE2, PAF, and vitronectin receptor. | 2006 | AIDS Res. Hum. Retroviruses | pmid:16910832 |
| Tsoupras AB et al. | Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? | 2008 | AIDS Res. Hum. Retroviruses | pmid:18620493 |
| Bertrand C et al. | Selective implication of thromboxane A2 and PAF-acether in two guinea pig anaphylactic models. | 1990 | Agents Actions Suppl. | pmid:2080755 |
| Tsunoda H et al. | Effects of a novel PAF antagonist, E6123, on PAF-induced biological responses. | 1990 | Agents Actions Suppl. | pmid:2080757 |
| Rihoux JP | The inhibiting effect of cetirizine 2 HC1 on eosinophil migration and its link to H1 blockade. | 1991 | Agents Actions Suppl. | pmid:1675836 |
| Parnham MJ et al. | Regulation of the oxidative burst of macrophages by lipid mediators. | 1984 | Agents Actions Suppl. | pmid:6433680 |
| Alabaster VA et al. | UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. | 1991 | Agents Actions Suppl. | pmid:1793066 |
| Heuer HO | The effects of hetrazepine PAF antagonists in preclinical models of asthma. | 1991 | Agents Actions Suppl. | pmid:1793067 |
| Mazzoni L et al. | Changes in airway sensitivity to histamine are not necessarily paralleled by changed sensitivity to acetylcholine. | 1991 | Agents Actions Suppl. | pmid:1793069 |
| Billah MM et al. | Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. | 1991 | Agents Actions Suppl. | pmid:1793070 |
| Saeed SA et al. | Inhibitory effect of oral ketotifen on ex vivo platelet activating factor-induced platelet aggregation. | 1991 | Agents Actions Suppl. | pmid:1793071 |
| Anderson GP and Fennessy MR | Lipoxygenase metabolites as mediators of platelet activating factor-induced increased airways responsiveness to histamine in the guinea-pig. | 1988 | Agents Actions Suppl. | pmid:3140616 |
| Page CP et al. | Drugs affecting pulmonary responses to platelet activating factor as novel anti-asthma drugs. | 1988 | Agents Actions Suppl. | pmid:3051932 |
| Hoshiko K et al. | Histamine(H1) antagonists and airway hyperreactivity in the guinea-pig. | 1991 | Agents Actions Suppl. | pmid:1686527 |
| Muirhead EE | Vasodepressor lipid of the renomedullary interstitial cells of the renal papilla is a prohormone activated by the liver. | 1987 | Agents Actions Suppl. | pmid:3324720 |
| Mest HJ et al. | Effect of BN 52256 and other mediator antagonists on ouabain-induced ventricular fibrillation in sensitized guinea-pigs and on ischemia-induced fibrillation in rats. | 1992 | Agents Actions Suppl. | pmid:1632298 |
| Koltai M and Braquet PG | Involvement of PAF in atherogenesis. Brief review. | 1992 | Agents Actions Suppl. | pmid:1632308 |
| Morley J et al. | Pharmacological evaluation of prophylactic anti-asthma drugs by reference to the pathological sequelae of exposure to allergen or platelet activating factor. | 1988 | Agents Actions Suppl. | pmid:3262989 |
| Subissi A and Criscuoli M | Effects of LG 30435 on different platelet activating factor-induced responses. | 1988 | Agents Actions Suppl. | pmid:3262990 |
| Heuer H and Casals-Stenzel J | Effect of the PAF-antagonist WEB 2086 on anaphylactic lung reaction: comparison of inhalative and intravenous challenge. | 1988 | Agents Actions Suppl. | pmid:3262991 |
| Etienne A et al. | Antithrombotic activity of BN 50341, a structurally new compound with anticalcic and PAF-antagonistic properties. | 1986 | Agents Actions Suppl. | pmid:3468781 |